ADMA Biologics
ADMA
163 hedge funds and large institutions have $547M invested in ADMA Biologics in 2023 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 64 increasing their positions, 43 reducing their positions, and 18 closing their positions.
116% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $930K
49% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 43
44% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 18
4.36% more ownership
Funds ownership: 70.06% → 74.42% (+4.4%)
3% more funds holding
Funds holding: 159 → 163 (+4)
8% less capital invested
Capital invested by funds: $592M → $547M (-$44.7M)
17% less funds holding in top 10
Funds holding in top 10: 6 → 5 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$14.9M |
| 2 |
State Street
Boston,
Massachusetts
|
+$6.85M |
| 3 |
Nuveen
Charlotte,
North Carolina
|
+$5.12M |
| 4 |
Two Sigma Advisers
New York
|
+$5M |
| 5 |
BlackRock
New York
|
+$4.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$6.96M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$5.33M |
| 3 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3.65M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$3.62M |
| 5 |
CP
Caligan Partners
New York
|
-$3.5M |
ADMA Hedge Fund Activity: Q1 2023 in Review
163 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q1 2023, worth a combined $547M — down 7.5% from $592M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ADMA positions and 18 closed out — a net gain of 8 holders — while 64 added to existing stakes and 43 trimmed.
The largest buyer was Assenagon Asset Management, adding an estimated $14.9M. The largest seller was Norges Bank, exiting entirely with an estimated $6.96M sold.
- 163 institutional investors held ADMA Biologics (ADMA) as of Q1 2023, up from 159 in Q4 2022.
- Funds reported $547M of ADMA Biologics stock for Q1 2023, down 7.5% quarter-over-quarter.
- 26 funds opened new ADMA Biologics positions in Q1 2023 and 18 closed out, a net change of +8 holders.
- The largest ADMA Biologics buyer in Q1 2023 was Assenagon Asset Management, an estimated $14.9M added.
- The largest ADMA Biologics seller in Q1 2023 was Norges Bank, an estimated $6.96M sold.
Based on aggregated 13F filings for Q1 2023.